Adenosine, Sleep Pressure, and Neuroinflammation
1 Huang et al. 2024 — Adenosine Receptors in Sleep Regulation
Full Citation:: Huang L, Zhu W, Li N, Zhang B, Dai W, Li S, Xu H@. Functions and mechanisms of adenosine and its receptors in sleep regulation. Sleep Medicine. 2024;115:210–217. DOI: 10.1016/j.sleep.2024.02.012. Key Findings::
- Adenosine promotes sleep by inhibiting arousal systems and activating sleep-promoting systems via A1 and A2A receptor subtypes
- Astrocyte-derived adenosine is the primary source of homeostatic sleep pressure signal
- Caffeine's wake-promoting effect is mediated entirely through adenosine receptor blockade
- A1 receptors inhibit wake-active neurons; A2A receptors in the nucleus accumbens core drive sleep pressureRelevance:: Establishes the mechanistic framework for adenosine as homeostatic sleep signal. Forms the foundational reference for Section 15.3 (Adenosine Accumulation and Pathological Sleep Pressure). Certainty Assessment::
- *Quality:* High (peer-reviewed review, Sleep Medicine)
- *Study type:* Narrative/mechanistic review
- *ME/CFS specificity:* None — establishes normal physiology
- *Limitation:* No primary data; no ME/CFS cohort2 Retéy et al. 2007 — ADORA2A Genotype and Caffeine Sensitivity}
Key Findings::
- ADORA2A c.1083T>C genotype distribution differs significantly between caffeine-sensitive and caffeine-insensitive adults
- Specific ADORA2A genotypes determine how closely caffeine-induced EEG changes resemble insomnia patterns
- Caffeine sensitivity is a functional readout of A2A receptor sensitivity at the individual levelRelevance:: Provides the pharmacogenetic basis for understanding ME/CFS patients’ variable caffeine responses as a potential marker of A2A receptor function. Supports the speculation that ME/CFS-associated A2A upregulation could alter caffeine pharmacodynamics. Certainty Assessment::
- *ME/CFS specificity:* None — general population caffeine-sleep study
- *Limitation:* No ME/CFS cohort; ME/CFS-specific caffeine-ADORA2A study remains unpublished3 Orr et al. 2009 — A2A Receptor Mediates Microglial Process Retraction
Full Citation:: Orr AG, Orr AL, Li X-J, Gross RE, Traynelis SF@. Adenosine A2A receptor mediates microglial process retraction. Nature Neuroscience. 2009;12(7):872–878. DOI: 10.1038/nn.2341. Key Findings::
- A2A adenosine receptors are upregulated on microglia coincident with P2Y12 downregulation during brain inflammation
- This receptor shift produces chemotactic reversal: activated microglia retract processes in response to adenosine (the ATP breakdown product) rather than extending toward it
- A2A signaling operates through Gs-adenylate cyclase-PKA pathway to drive amoeboid microglial morphology
- Human microglia show the same receptor expression pattern as mouse modelsRelevance:: Seminal mechanistic paper establishing the A2A upregulation-neuroinflammation link. Directly supports the hypothesis in Section 15.3 that ME/CFS neuroinflammation maintains elevated A2A receptor density in sleep-regulatory brain regions. Certainty Assessment::
- *Quality:* High (Nature Neuroscience, top-tier journal)
- *Study type:* Primary mechanistic (mouse + human cell data)
- *ME/CFS specificity:* None — mechanism study
- *Limitation:* In vitro/animal model; extrapolation to ME/CFS requires supporting in vivo evidence5 Chang et al. 2021 — Dysregulated Adenosine Homeostasis in Brain Disorders
Full Citation:: Chang C-P, Wu K-C, Lin C-Y, Chern Y@. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. Journal of Biomedical Science. 2021;28(1):70. DOI: 10.1186/s12929-021-00766-y. Key Findings::
- Adenosine homeostasis is regulated by ectonucleotidases (CD39, CD73), adenosine deaminase (ADA), and equilibrative nucleoside transporters (ENT1/ENT2)
- Dysregulation of any component leads to aberrant extracellular adenosine accumulation
- In neuroinflammatory and neurodegenerative conditions, impaired clearance through glial transporters is a consistent finding
- Adenosine functions as an endogenous anti-inflammatory agent; its dysregulation sustains microglial activation in a positive feedback loopRelevance:: Establishes the molecular machinery of adenosine clearance relevant to Section 15.3. ME/CFS reactive astrogliosis would be predicted to impair ENT1/ENT2-mediated clearance, raising basal adenosine. Certainty Assessment::
- *Quality:* High (Journal of Biomedical Science, comprehensive review)
- *ME/CFS specificity:* None — focused on neurodegeneration
- *Limitation:* Mechanistic extrapolation to ME/CFS; no direct measurement of ENT expression in ME/CFS glia6 Rábago-Monzón et al. 2025 — Astrocytes, Microglia, and Sleep Dysregulation}
Full Citation:: Rábago-Monzón AR, Osuna-Ramos JF, Armienta-Rojas DA, et al. Stress-Induced Sleep Dysregulation: The Roles of Astrocytes and Microglia in Neurodegenerative and Psychiatric Disorders. Biomedicines. 2025;13(5):1121. DOI: 10.3390/biomedicines13051121. Key Findings::
- Astrocytes regulate sleep architecture via two primary mechanisms: adenosine signaling and glymphatic clearance
- Chronic stress disrupts both pathways, reducing restorative sleep quality
- Microglial neuroinflammation further degrades sleep quality through synaptic dysfunction
- Convergence of adenosine dysregulation and glymphatic failure on synaptic pruning and plasticity is documentedRelevance:: Directly links the glial biology of ME/CFS (neuroinflammation, reactive astrogliosis) to the sleep complaints that are central to the disease. Supports the integration of Section 15.3 with Section 15.10 (glymphatic failure). Certainty Assessment::
- *Quality:* Medium (Biomedicines, mechanistic synthesis review; 2025)
- *ME/CFS specificity:* None
- *Limitation:* Synthesis paper; primary data for ME/CFS application is indirect7 Nakatomi et al. 2014 — TSPO-PET Neuroinflammation in ME/CFS
Full Citation:: Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study. Journal of Nuclear Medicine. 2014;55(6):945–950. DOI: 10.2967/jnumed.113.131045. Key Findings::
- TSPO binding (microglial activation marker) elevated 45–199% in ME/CFS patients vs.\ healthy controls
- Affected regions: cingulate cortex, hippocampus, amygdala, thalamus, midbrain, pons
- Regional neuroinflammation correlated with cognitive impairment, pain, and depression severity
- First direct in vivo neuroinflammation evidence in ME/CFS via PET imagingRelevance:: Landmark study providing the neuroinflammatory substrate that mechanistically supports A2A upregulation and adenosine dysregulation in ME/CFS. The affected brain regions overlap substantially with sleep-regulatory circuitry (cingulate, thalamus, brainstem). Certainty Assessment::
- *Quality:* High (Journal of Nuclear Medicine; in vivo patient data)
- *Sample:* n=9 ME/CFS patients, n=10 healthy controls
- *Replication:* Partially replicated by subsequent PET and MRS studies (Younger group)
- *Limitation:* Small sample; single centre; TSPO binding is a marker of glial activation, not exclusive to microglia8 Maksoud et al. 2021 — Systematic Review of Sleep in ME/CFS
Full Citation:: Maksoud R, Eaton-Fitch N, Matula M, Cabanas H, Staines D, Marshall-Gradisnik S@. Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Healthcare. 2021;9(5):568. DOI: 10.3390/healthcare9050568. Key Findings::
- Non-restorative sleep reported by approximately 91% of ME/CFS patients
- Increased microarousal index (MAI) is the single most consistent polysomnographic abnormality: elevated in all five studies that measured it
- Sleep onset latency is uniformly normal across 13 studies — sleep initiation is intact
- Major discrepancy between subjective sleep complaints and aggregate polysomnographic measures
- Pattern suggests pathology in sleep maintenance and quality, not in sleep initiationRelevance:: Provides the clinical sleep phenotype that the adenosine hypothesis in Section 15.3 must explain. The preserved sleep onset latency with elevated microarousal index is mechanistically consistent with adenosine-mediated sleep maintenance disruption rather than a simple sleep pressure deficit. Certainty Assessment::
- *Quality:* High (systematic review, Healthcare)
- *Study type:* Systematic review of polysomnographic studies
- *Limitation:* Heterogeneous populations and methods across included studies; no biomarker data linking sleep findings to adenosine specifically9 Section 15.6 — Melatonin Dysfunction and Circadian Disruption
9.1 McCarthy 2022 — Circadian Rhythm Disruption in ME/CFS and Long COVID
Key Findings::
- ME/CFS patients lack the midday temperature increase seen in healthy controls and show a distinct evening temperature drop, indicating multi-system circadian decoupling beyond melatonin timing alone
- DLMO timing is dissociated from body temperature rhythm in ME/CFS (both rhythms correlate in controls; correlation absent in patients)
- TGFB (transforming growth factor beta) dysregulation proposed as mechanistic driver of peripheral clock disruption via SMAD protein signaling
- Melatonin treatment shows preferential benefit only in the phase-delayed subset of ME/CFS patients
- ME/CFS findings may illuminate long COVID (PASC) pathophysiology given shared circadian disruptionRelevance:: Provides the mechanistic framework for Section 15.6, establishing that circadian disruption in ME/CFS is multi-system and not reducible to simple delayed DLMO. The TGFB link connects circadian dysfunction to the immune dysregulation documented elsewhere in the chapter. Certainty Assessment::
- *Quality:* Medium (narrative review, single author, Brain Behav Immun Health)
- *Study type:* Narrative review
- *Limitation:* No new primary data; synthesises older studies with heterogeneous methods; TGFB mechanistic link is theoretical9.2 van Heukelom et al. 2006 — Melatonin for CFS with Late DLMO
Heukelom et al. (2006)
Key Findings::
- 29 CFS patients with DLMO $>$ 21:30h treated with 5mg melatonin orally 5h before DLMO for 3 months
- CIS total score and sub-scores (fatigue, concentration, motivation, activity) all improved significantly post-treatment
- Fatigue normalized in 8/27 patients during treatment vs.\ 2/29 pre-treatment ($p < 0.05$)
- Patients with DLMO $>$ 22:00h ($n=21$) showed significantly greater benefit than those with DLMO 21:30–22:00h ($n=8$)
- Supports DLMO-guided timing as a clinically meaningful stratification variableRelevance:: Primary ME/CFS-specific evidence for melatonin treatment stratified by DLMO. Directly supports the therapeutic approach described in Section 15.6 and the rationale for DLMO assessment before prescribing melatonin. Certainty Assessment::
- *Quality:* Medium (European Journal of Neurology, peer-reviewed)
- *Sample:* n=29
- *Replication:* Not replicated as a controlled trial
- *Limitation:* Open-label, no placebo control; significant pre-treatment improvement in fatigue sub-score complicates attribution9.3 Knook et al. 2000 — High Nocturnal Melatonin in Adolescent ME/CFS
Key Findings::
- 13 adolescent CFS patients showed significantly elevated nocturnal salivary melatonin at midnight, 01:00h, and 02:00h compared to 15 controls ($p < 0.001$)
- Timing of melatonin rise did not differ between groups — amplitude, not phase, was abnormal
- All CFS patients reported unrefreshing sleep vs.\ only 1 control, despite similar sleep-onset time and duration
- Authors concluded melatonin supplementation is not indicated in this subgroupRelevance:: Demonstrates phenotypic heterogeneity in ME/CFS melatonin abnormalities: elevated amplitude (adolescents) vs. delayed phase (adults). Critical for Section 15.6 to avoid overgeneralising treatment recommendations and to frame melatonin abnormalities as bidirectional. Certainty Assessment::
- *Quality:* Medium (J Clin Endocrinol Metab, peer-reviewed)
- *Sample:* n=13 patients, n=15 controls
- *Replication:* Not replicated; small sample
- *Limitation:* Very small sample; adolescent-only; no adult comparison arm9.4 Mohamed et al. 2023 — Objective Sleep Measures in ME/CFS: Meta-Analysis
Key Findings::
- Largest meta-analysis of objective sleep measures in ME/CFS: 24 studies, 801 adults and 477 adolescents
- Adults: longer sleep onset latency, longer wake after sleep onset (WASO), reduced sleep efficiency, decreased stage N2, more stage N3 (slow-wave sleep), longer REM latency
- Adolescents: longer TIB, longer TST, longer SOL, reduced sleep efficiency
- Paradoxical increase in slow-wave sleep despite unrefreshing experience suggests quality impairment, not simply quantity reduction
- Findings suggest sympathetic/parasympathetic nervous system alterations contribute to sleep disruptionRelevance:: Provides the sleep architecture phenotype that melatonin dysfunction must help explain. The preserved or increased SWS alongside unrefreshing sleep is mechanistically important: circadian misalignment may fragment the restorative quality of SWS without reducing its measured duration. Certainty Assessment::
- *Quality:* High (Sleep Medicine Reviews, systematic review and meta-analysis)
- *Sample:* 24 studies, 1278 total participants
- *Replication:* Meta-analytic synthesis across multiple independent cohorts
- *Limitation:* Heterogeneity across included studies; no direct melatonin measurement data; no conflicts of interest9.5 Gotts et al. 2015 — Daytime Napping and Cognitive Functioning in CFS
Key Findings::
- N=118 CFS patients (Fukuda criteria), 14-day sleep diary with standardized neuropsychological testing
- Afternoon napping predicted worse objective cognitive dysfunction, explaining 25.6% of variance (p\<.001)
- Morning napping predicted worse subjective cognitive dysfunction, explaining 32.2% of variance
- Longer nap duration and afternoon nap timing both associated with greater daytime sleepiness
- No experimental manipulation — purely observational associationRelevance:: First study to quantify the nap–cognition association in CFS. The finding that napping predicts worse cognitive outcomes (rather than restoration) is consistent with the nap pathophysiology framework: alpha-delta intrusion during naps prevents restorative sleep stages, adenosine regenerates immediately post-nap due to metabolic deficit, and prolonged naps trigger amplified sleep inertia. Causal direction unclear — napping may reflect greater disease severity rather than causing cognitive decline. Certainty Assessment::
- *Quality:* Medium (PLoS ONE, observational design)
- *Sample:* n=118, reasonable size for ME/CFS
- *Replication:* Not yet replicated; single study
- *Limitation:* Cross-sectional; no EEG during naps; cannot distinguish cause from effect; Fukuda criteria (broader than CCC/ICC)9.6 Tassi & Muzet 2000 — Sleep Inertia Review
Key Findings::
- Sleep inertia (transient lowered arousal post-awakening) lasts 1 minute to 4 hours depending on conditions
- Rarely exceeds 30 minutes without major sleep deprivation in healthy populations
- Most severe after awakening from slow-wave sleep --- naps \>30 minutes entering deep sleep produce worse inertia than naps \<20 minutes
- Dose-dependent with prior sleep debt; circadian modulation (worse near core body temperature trough)
- Different cognitive tasks show different sensitivity to sleep inertiaRelevance:: Foundational reference for understanding amplified sleep inertia in ME/CFS. The normal 15–30 minute duration becomes 2–4 hours in ME/CFS patients (clinical observation, not yet formally measured). The SWS-awakening mechanism predicts that ME/CFS patients with preserved SWS entry during long naps will experience severe inertia, while the energy-deficit model predicts that state transitions (sleep → wake) are metabolically demanding and fail preferentially in ME/CFS. Together, these predict that long naps are counterproductive: they enter SWS (triggering inertia) in a brain unable to execute the wake-transition (prolonging inertia). Certainty Assessment::
- *Quality:* High (Sleep Medicine Reviews, comprehensive narrative review)
- *Sample:* Review of multiple studies across healthy populations
- *Replication:* Sleep inertia phenomenon well-replicated across many studies
- *Limitation:* No ME/CFS-specific data; ME/CFS sleep inertia duration never formally measured10 Meditation, Mind-Body Interventions, and Sensory Rest
The central clinical challenge for meditation/mindfulness in ME/CFS is that cognitive effort is itself a physiological stressor capable of triggering post-exertional malaise. Standard meditation protocols (concentration on breath, prolonged guided visualization, group retreat formats) impose cognitive load that may exceed patients’ energy envelope. The distinction between passive practices (body scan, yoga nidra, sensory deprivation, lying still) and active practices (effortful concentration, sustained attention, visualization) is clinically critical but largely unexamined in the existing trial literature.
10.1 Khanpour Ardestani et al. 2021 — Systematic Review of Mind-Body Interventions
(Khanpour Ardestani et al. 2021)
Full Citation:: Khanpour Ardestani S, Karkhaneh M, Stein E, Punja S, Junqueira DR, Kuzmyn T, Pearson M, Smith L, Olson K, Vohra S@. Systematic Review of Mind-Body Interventions to Treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Medicina (Kaunas). 2021;57(7):652. DOI: 10.3390/medicina57070652. PMID:: 34202826 Study Design:: Systematic review; 12 studies (7 RCTs); interventions included MBSR, MBCT, relaxation, Qigong, CBT-stress management, acceptance and commitment therapy, and isometric yoga Key Findings::
- 9 of 12 studies showed fatigue severity improvement; 8 of 12 showed anxiety/depression reduction
- Physical and mental functioning improved in 3 studies
- Interventions were heterogeneous; no head-to-head comparisons
- Critical limitation: diagnostic criteria varied across studies; many used Fukuda (broader) rather than CCC or ICC
- High risk of bias across most included studies; small samples throughout
- No adverse event tracking in the majority of studiesRelevance:: Best available evidence synthesis for mind-body interventions in ME/CFS. The positive signal across heterogeneous studies is consistent with benefit, but the active component cannot be isolated: improvement may reflect rest, acceptance, reduced catastrophizing, social contact, or direct physiological effects of specific practices. Cannot determine whether standard MBSR (cognitively demanding for severely ill patients) or low-exertion adapted forms (isometric yoga, body scan alone) drive efficacy. Certainty Assessment::
- *Quality:* Medium (Medicina, systematic review; heterogeneous evidence base)
- *Sample:* 12 studies pooled; individual trial n ranges approximately 12--100
- *Replication:* Multiple studies show directional consistency; no replications of specific protocols
- *Limitation:* Heterogeneous criteria, small samples, high bias risk, no adverse event tracking, cannot isolate active component10.2 Sampalli et al. 2009 — MBSR Controlled Trial: MCS, CFS, and Fibromyalgia
Full Citation:: Sampalli T, Berlasso E, Fox R, Petter M@. A controlled study of the effect of a mindfulness-based stress reduction technique in women with multiple chemical sensitivity, chronic fatigue syndrome, and fibromyalgia. Journal of Multidisciplinary Healthcare. 2009;2:53–59. DOI: 10.2147/jmdh.s5220. PMID:: 21197347 Study Design:: Controlled (non-randomized) trial; 10-week MBSR program; n=50 intervention, n=26 waitlist controls; all women with MCS, CFS, or fibromyalgia Key Findings::
- SCL-90R global symptom index: statistically significant pre-post improvement (p\<0.0001) and maintained at 3-month follow-up in intervention group
- Waitlist control group: no significant change over same period
- Three-month durability suggests effects beyond immediate relaxation response
- MBSR standard format = 2.5h/week group sessions + daily home practice (45 min/day); cognitively demanding schedule for severe ME/CFS patients
- Study population mixed (MCS + CFS + FM) -- CFS-specific effect cannot be isolatedRelevance:: Provides evidence that MBSR produces durable symptom reduction in a mixed chronic-illness population including CFS. However, the non-randomized design and mixed population limit CFS-specific conclusions. The standard MBSR format represents a high cognitive and time commitment; severely ill ME/CFS patients may not tolerate it. The result may reflect the rest component (lying during body scan; reduced activity) rather than cognitive mindfulness training per se. Certainty Assessment::
- *Quality:* Medium (non-randomized controlled design; self-selected groups)
- *Sample:* n=76 total; CFS subgroup size not reported separately
- *Replication:* Not independently replicated in CFS-specific cohort
- *Limitation:* Non-randomized; mixed diagnosis; cognitively demanding format untested for severe ME/CFS; no adverse events reported10.3 Lakhan & Schofield 2013 — Meta-Analysis of Mindfulness for Somatization Disorders
Full Citation:: Lakhan SE, Schofield KL@. Mindfulness-based therapies in the treatment of somatization disorders: a systematic review and meta-analysis. PLoS ONE. 2013;8(8):e71834. DOI: 10.1371/journal.pone.0071834. PMID:: 23990997 Study Design:: Meta-analysis; 13 RCTs; mindfulness-based therapies (MBSR, MBCT, mindfulness-based CBT) for somatization disorders including CFS Key Findings::
- Small-to-moderate positive effect on somatic symptom severity (SMD = --0.40)
- Small-to-moderate effect on quality of life (SMD = 0.39)
- Benefits consistent across pain, depression, anxiety sub-scores
- Greatest efficacy for IBS; CFS included but not isolated as subgroup
- MBSR and MBCT showed greater efficacy than eclectic approachesRelevance:: Provides the broadest pooled evidence for mindfulness benefit in conditions overlapping with ME/CFS. The SMD of approximately 0.40 is clinically modest but statistically consistent. The IBS-dominant efficacy signal may reflect gut-brain mechanisms rather than central fatigue pathways, limiting direct extrapolation to ME/CFS. CFS is not a primary somatization disorder under current understanding; inclusion in somatization reviews is itself a contested nosological position. Certainty Assessment::
- *Quality:* Medium (PLoS ONE; pooled across heterogeneous populations)
- *Sample:* 13 RCTs; total n not specified for CFS subgroup
- *Replication:* Meta-analytic pooling; consistent signal across studies
- *Limitation:* CFS not isolated; somatization framing contested; cannot distinguish rest from mindfulness as active component10.4 Merkes 2010 — MBSR for Chronic Diseases: Systematic Review
Full Citation:: Merkes M@. Mindfulness-based stress reduction for people with chronic diseases. Australian Journal of Primary Health. 2010;16(3):200–210. DOI: 10.1071/PY09063. PMID:: 20815988 Study Design:: Systematic review; 15 peer-reviewed studies; MBSR programs for chronic conditions including cancer, anxiety, HIV, fibromyalgia, and chronic fatigue syndrome Key Findings::
- All 15 studies reported improvements on primary outcome measures; no negative outcomes documented
- Benefits reported across mental health, QoL, pain, fatigue, and functional status domains
- No adverse events documented across any study
- Methodological quality variable; most studies pre-dated CONSORT reporting standardsRelevance:: Provides the broadest positive signal for MBSR in chronic conditions. The uniform positive finding across all 15 studies is consistent with benefit but also reflects publication bias: negative or null MBSR trials are underrepresented in the literature. The absence of adverse event tracking is particularly problematic for ME/CFS, where standard MBSR (45-minute daily home practice, 2.5h weekly sessions) imposes significant cognitive load. Should be cited with explicit acknowledgment of publication bias and absence of harm data. Certainty Assessment::
- *Quality:* Low-to-Medium (narrative systematic review; publication bias acknowledged; no meta-analytic pooling)
- *Sample:* 15 studies; CFS-specific subgroup not isolated
- *Replication:* Multiple studies consistent in direction; likely publication bias
- *Limitation:* Narrative only; CFS not isolated; no adverse event data; pre-CONSORT methods; ME/CFS-specific cognitive load of MBSR not addressed10.5 Oka et al. 2014 — Isometric Yoga RCT: Seated, Non-Aerobic
Full Citation:: Oka T, Tanahashi T, Chijiwa T, Lkhagvasuren B, Sudo N, Oka K@. Isometric yoga improves the fatigue and pain of patients with chronic fatigue syndrome who are resistant to conventional therapy: a randomized, controlled trial. Biopsychosocial Medicine. 2014;8(1):27. DOI: 10.1186/s13030-014-0027-8. PMID:: 25525457 Study Design:: RCT; n=30 therapy-resistant CFS patients (Fukuda criteria); biweekly instructor sessions + daily home practice; 2 months; waitlist control Key Findings::
- Chalder Fatigue Scale (CFS): yoga group 25.9 $\pm$ 6.1 → 19.2 $\pm$ 7.5 (p=0.002); control no significant change
- Post-session mood fatigue scores improved immediately (p\<0.05); body warmth and pain relief reported
- Isometric yoga involves static muscle contractions *without joint movement* --- no aerobic demand, no balance challenge, performed seated
- Key differentiator: removes cardiovascular exertion component that would trigger PEM in ME/CFS
- Single center (Kyushu University, Japan); no blinding possible; Fukuda criteria (broader than CCC/ICC)Relevance:: Best-quality RCT evidence for an adapted yoga format compatible with ME/CFS energy envelope constraints. Isometric contractions without movement represent a distinct physiological category from aerobic or standard yoga practice. The parasympathetic shift observed (Oka 2018) may explain why this format avoids post-exertional worsening. Directly relevant to ch17 treatment recommendations. Certainty Assessment::
- *Quality:* Medium (Biopsychosocial Medicine; small RCT; single center)
- *Sample:* n=30 (15 yoga, 15 control)
- *Replication:* Partially --- Oka group published multiple follow-up studies; independent replication absent
- *Limitation:* No blinding; Fukuda criteria; short follow-up (2 months); Japan-specific setting; no PEM monitoring10.6 Oka et al. 2017 — Recumbent Isometric Yoga for Severe ME/CFS
(Oka, Wakita, and Kimura 2017)
Full Citation:: Oka T, Wakita H, Kimura K@. Development of a recumbent isometric yoga program for patients with severe chronic fatigue syndrome/myalgic encephalomyelitis: A pilot study to assess feasibility and efficacy. Biopsychosocial Medicine. 2017;11:5. DOI: 10.1186/s13030-017-0090-z. PMID:: 28270860 Study Design:: Pilot study; n=12 severe ME/CFS; no control group; recumbent (supine) format × 3 months; two groups by severity Key Findings::
- Both groups: significant fatigue reduction (Chalder FS) over 3 months
- Recumbent format preferred unanimously by group 2 (more severe) patients
- No serious adverse events; no PEM worsening reported
- Recumbent position eliminates orthostatic challenge --- eliminates OI-related autonomic destabilization during practice
- Clinically accessible for patients unable to attend outpatient clinic (home-based option explored)Relevance:: Extends isometric yoga evidence to the most severely affected ME/CFS patients. Recumbent format directly addresses orthostatic intolerance — the most common barrier to physical activity in severe ME/CFS. No control group means efficacy interpretation is limited, but safety signal is important: no PEM worsening in a very vulnerable population. Provides the practical template for adapted practice. Certainty Assessment::
- *Quality:* Low (pilot; no control; n=12; single center)
- *Sample:* n=12
- *Replication:* Not independently replicated
- *Limitation:* No control; very small n; same research group as Oka 2014/2018; selection bias possible (participants willing to try yoga)10.7 Oka et al. 2018 — Mechanisms: Autonomic and Biomarker Effects
Full Citation:: Oka T, Tanahashi T, Sudo N, Lkhagvasuren B, Yamada Y@. Changes in fatigue, autonomic functions, and blood biomarkers due to sitting isometric yoga in patients with chronic fatigue syndrome. Biopsychosocial Medicine. 2018;12:3. DOI: 10.1186/s13030-018-0123-2. PMID:: 29643935 Study Design:: Mechanistic study (pre-post single session); n=15 CFS patients; seated isometric yoga session; autonomic monitoring (HRV) + blood biomarkers Key Findings::
- POMS fatigue score: reduced (p\<0.01); vigor: increased (p\<0.01) immediately post-session
- Reduced heart rate, increased HF-HRV power (vagal tone up)
- Decreased cortisol (anti-stress signal) and TNF-$\alpha$ (anti-inflammatory)
- Increased DHEA-S (adrenal reserve marker; opposite direction to exertion-stress response)
- Biomarker profile: parasympathetic dominance + reduced inflammation, NOT the cortisol/IL-6 spike seen after aerobic exertionRelevance:: Mechanistic evidence that isometric yoga does not produce the physiological stress signature that triggers PEM in ME/CFS. The cortisol decrease + TNF-\(\alpha\) decrease + vagal increase is the opposite profile from exercise-induced PEM. This distinguishes isometric yoga from aerobic exertion at the biomarker level, providing a mechanistic rationale for why this specific form is tolerable. Relevant to ch15 mechanism discussion (cognitive/physical exertion triggers). Certainty Assessment::
- *Quality:* Medium (Biopsychosocial Medicine; mechanistic; n=15; single session only)
- *Sample:* n=15
- *Replication:* Biomarker findings consistent with Oka 2019 (longitudinal); not independently replicated
- *Limitation:* Single time point; no blinding; no long-term biomarker tracking; same group as other Oka studies10.8 O’Connor et al. 2019 — Energy Envelope Theory: Pacing Framework
Full Citation:: O’Connor K, Sunnquist M, Nicholson L, Jason LA, Newton JL, Strand EB@. Energy envelope maintenance among patients with myalgic encephalomyelitis and chronic fatigue syndrome: Implications of limited energy reserves. Chronic Illness. 2019;15(1):51–60. DOI: 10.1177/1742395317746470. PMID:: 29231037 Study Design:: Cross-sectional; six groups stratified by available energy level and envelope adherence Key Findings::
- Higher available energy + within-envelope exertion = best functional outcomes
- Overexertion diminishes the functional advantage of higher available energy
- Patients who stay within their energy envelope show better functioning regardless of absolute energy level
- Framework applies equally to cognitive and physical exertion — mental effort draws from the same limited energy reserveRelevance:: Provides the theoretical and empirical framework for all ME/CFS rest and activity recommendations including meditation adaptation. Cognitive exertion (effortful concentration meditation, prolonged guided visualization) must be treated identically to physical exertion within the pacing framework. Passive practices that minimize cognitive demand (body scan without sustained attention requirements, yoga nidra, lying still with sensory reduction) respect the energy envelope; standard MBSR programs with 2.5h/week structured sessions may not. Certainty Assessment::
- *Quality:* Medium (Chronic Illness; cross-sectional; well-established theory)
- *Sample:* Sample size not specified in abstract; grouped stratification design
- *Replication:* Energy envelope concept well-supported across multiple Jason lab publications
- *Limitation:* Cross-sectional; self-reported energy levels; causality not established10.9 Burgess et al. 2010 — Phase Response Curves: 0.5mg vs 3.0mg Melatonin
Key Findings::
- Maximum circadian phase advances with 0.5mg melatonin occurred 2–4h before DLMO or 9–11h before sleep midpoint
- When given at optimal timing, both 0.5mg and 3.0mg produce similarly sized phase advances and delays
- Optimal administration time for advances is later for the lower (0.5mg) dose
- Low-dose melatonin avoids pharmacological sedation and supraphysiological blood levels that may suppress endogenous pineal secretionRelevance:: Provides the pharmacological rationale for low-dose melatonin (0.5mg) as preferred therapeutic dosing in ME/CFS. Since endogenous melatonin function is already abnormal, avoiding suppression of residual secretion is clinically important. Directly supports the dosing recommendations in Section 15.6. Certainty Assessment::
- *Quality:* High (J Clin Endocrinol Metab, double-blind placebo-controlled trial in healthy adults)
- *Sample:* n=34 healthy adults
- *Replication:* Foundational PRC study; findings consistent with prior melatonin PRC literature
- *Limitation:* Healthy adults only; ME/CFS-specific PRC not characterized; extrapolation required10.10 Swanson et al. 2024 — Low-Dose Melatonin + Dim Light for DSWPD
Key Findings::
- RCT ($n=40$, DSWPD): 0.5mg melatonin timed to measured or estimated DLMO, plus evening dim light and time-in-bed scheduling for 4 weeks
- Significant improvements in DLMO timing, sleep-onset and sleep-offset, Morningness-Eveningness score, fatigue (MFI), and PROMIS sleep disturbance/impairment (Bonferroni corrected)
- No significant difference between groups: DLMO estimation via actigraphy was as effective as formal DLMO measurement for scheduling melatonin
- Multimodal approach (melatonin + light hygiene + scheduling) appears synergisticRelevance:: Most clinically applicable RCT for the Section 15.6 treatment strategy. Supports multi-modal approach combining low-dose melatonin with circadian hygiene measures. The equivalence of estimated vs. measured DLMO has practical implications for clinical settings where formal DLMO testing is unavailable. Certainty Assessment::
- *Quality:* High (J Clin Sleep Med, RCT)
- *Sample:* n=40
- *Replication:* Preliminary; authors state larger confirmatory trial needed
- *Limitation:* DSWPD patients, not ME/CFS; Burgess has industry advisory relationship (Natrol LLC)10.11 Reiter et al. 2016 — Melatonin as Mitochondria-Targeted Antioxidant
Key Findings::
- Melatonin concentrations in mitochondria greatly exceed blood levels, establishing it as a mitochondria-targeted antioxidant
- Mechanisms: direct ROS/RNS scavenging; stimulation of SOD, GPx, catalase; suppression of pro-oxidant enzymes; transition metal chelation
- Metabolites AFMK and AMK retain antioxidant activity, providing a “cascade” of protection
- Effective against ischaemia/reperfusion injury in brain and heart; combats drug toxicity and chemotherapy resistanceRelevance:: Provides the biochemical basis for melatonin’s antioxidant role referenced in both Section 15.6 and Section 15.12 (Oxidative and Nitrosative Stress). In ME/CFS, where mitochondrial dysfunction and oxidative stress co-occur, melatonin deficiency or disruption may amplify ROS accumulation. Foundational reference for the antioxidant pathway. Certainty Assessment::
- *Quality:* High (Journal of Pineal Research, comprehensive review by leading melatonin researchers)
- *Study type:* Narrative/mechanistic review
- *Limitation:* Predominantly animal and in vitro data; human RCT evidence for antioxidant effects in chronic disease is limited; no conflicts stated10.12 Liang et al. 2024 — Melatonin Enhances NK Cell Function via JAK3-STAT5
Key Findings::
- Melatonin significantly increased NK cell number, proliferation, degranulation, and IFN-$\gamma$ secretion in aged mice
- Mechanism: JAK3/STAT5 signaling pathway → increased T-bet expression → NK cell maturation and activation
- Provides molecular mechanism linking melatonin to NK cell function, relevant to ME/CFS NK hypofunctionalityRelevance:: NK cell cytotoxicity is consistently reduced in ME/CFS. This paper provides a mechanistic explanation for how circadian disruption and melatonin deficiency could contribute to NK dysfunction: loss of melatonin-driven JAK3/STAT5/T-bet signaling. Directly supports the melatonin–immune axis discussion in Section 15.6. Certainty Assessment::
[- Quality: Medium (Immunity, Ageing), open access, peer-reviewed],
- *Sample:* Animal model (aged mice); no human data
- *Replication:* Single study; mechanistic pathway not yet confirmed in humans
- *Limitation:* Mouse model only; extrapolation to human ME/CFS is speculative; erratum published (minor correction)Key Findings::
- Proposes gut and immune cell mitochondria as two central hubs in ME/CFS pathophysiology
- Circadian rhythm and melatonin identified as upstream regulatory factors interacting with mitochondrial function
- Also implicates gut microbiome/permeability, endogenous opioidergic system, autonomic nervous system, microRNA-155, viral reactivation, and leptin
- Positions melatonin/circadian disruption as an upstream driver that compounds mitochondrial and immune dysfunctionRelevance:: Provides the integrative framework connecting Section 15.6 (melatonin/circadian) to the bioenergetic and immune dysfunction chapters. Useful for establishing why melatonin interventions may have effects beyond sleep, reaching mitochondrial function and immune regulation. Certainty Assessment::
- *Quality:* Medium (Progress in Neuropsychopharmacology and Biological Psychiatry, review)
- *Study type:* Narrative review
- *Limitation:* Theoretical/mechanistic; most proposed interactions not yet tested experimentally in ME/CFS; authors (Anderson, Maes) have published extensively in this theoretical space — assess for confirmation bias11 Section 15.7: Microglia Activation and Neuroinflammatory Fatigue
(VanElzakker, Brumfield, and Lara Mejia 2019)
Key Findings::
- Critical methodological review of PET, MRS, and cytokine assay approaches to measuring neuroinflammation in ME/CFS
- Most neuroimaging studies inadequately target the brainstem, which is proposed as probable primary site of neuroinflammatory activity
- Peripheral cytokine profiling unreliable for diagnosis due to measurement variability and biological complexity
- Positions TSPO-PET as the strongest available method but notes second-generation ligands needed to overcome binding potential issues of PK11195Relevance:: Essential methodological reference for interpreting the heterogeneous neuroinflammation literature. Contextualises why the Nakatomi 2014 and Raijmakers 2021 TSPO-PET studies reach contradictory conclusions. Argues that future studies must target brainstem specifically. Certainty Assessment::
- *Quality:* High (Frontiers in Neurology; peer-reviewed methods review)
- *Study type:* Critical review — no new empirical data
- *Limitation:* Cannot resolve empirical contradictions in the primary literature; advocates for better methods rather than providing themKey Findings::
- Proposes impaired or pathologically reactive neuroglia (astrocytes, microglia, oligodendrocytes) as the common pathobiological denominator in ME/CFS
- Reactive microglia shift to M1-like state, releasing TNF-$\alpha$, IL-1$\beta$, IL-6, and reactive oxygen species, suppressing neural circuit efficiency
- Complement cascade (C1q, C3) may drive excess synaptic pruning by activated microglia, contributing to cognitive symptoms
- Neuroglial failure could explain post-exertional malaise: during activity, glial metabolic support to neurons fails under increased demand
- Directly applicable to Long COVID, which shows similar neuroglial activation on post-mortem analysisRelevance:: Provides the integrative mechanistic framework for Section 15.7. Connects microglia M1/M2 phenotypes, complement activation, synaptic pruning excess, and PEM into a single explanatory model. Co-authored by Marie-Eve Tremblay, a leading microglia researcher. Certainty Assessment::
- *Quality:* High (Frontiers in Cellular Neuroscience; expert authorship)
- *Study type:* Hypothesis/narrative review — no original data
- *Limitation:* Theoretical synthesis; individual component mechanisms extrapolated from other diseases (Alzheimer's, MS, viral encephalitis); not yet tested as a unified hypothesis in ME/CFS specificallyKey Findings::
- ME/CFS patient serum directly stimulates reactive oxygen species (ROS) and nitric oxide production in human HMC3 microglial cells *in vitro*
- ATG13 (autophagy-related protein 13), elevated in ME/CFS serum, identified as the active factor via RAGE receptors on microglia
- ATG13 neutralisation substantially reduces the microglial oxidative stress response
- Provides a mechanistic link between impaired autophagy (a peripheral ME/CFS feature) and central microglial activationRelevance:: Supports the circulating-factors model of neuroinflammation: peripheral ME/CFS abnormalities can directly activate brain microglia. Provides a specific molecular mechanism (ATG13/RAGE axis) amenable to therapeutic targeting. Certainty Assessment::
- *Quality:* Medium (Molecular and Cellular Neuroscience; peer-reviewed)
- *Study type:* In vitro mechanistic study (HMC3 cell line)
- *Sample:* Human serum from ME/CFS patients (sample size not reported in abstract)
- *Limitation:* In vitro only; does not demonstrate the mechanism operates at equivalent magnitude in living patients; cell line model (HMC3) is not primary human microglia; single study needing replication11.1 Miwa 2021 — Oral Minocycline Trial in Myalgic Encephalomyelitis
Key Findings::
- Open-label prospective trial: oral minocycline 100 mg/day for 42 days in 100 ME patients
- Favourable response (performance status improvement ≥2 points) in 27 patients (27%)
- Best response in patients within 6 months of disease onset
- Rationale: minocycline inhibits microglial activation and exerts anti-inflammatory, immunomodulatory, and neuroprotective effects
- 38% discontinued due to adverse effects (nausea, dizziness, photosensitivity)Relevance:: Primary clinical evidence for minocycline as a microglial modulator in ME/CFS. Supports the hypothesis that neuroinflammation is most therapeutically accessible in early-stage disease. Directly relevant to Section 15.7 therapeutic strategies discussion. Certainty Assessment::
- *Quality:* Low-Medium (Internal Medicine; open-label single-arm)
- *Sample:* n=100
- *Study type:* Open-label prospective; no control group; no blinding; Japanese single-centre
- *Limitation:* No randomisation; significant dropout (38%); Japanese cohort may not generalize; response rate (27%) modest; performance status is a subjective endpoint
- *Replication:* Partially replicated in Miwa 2024 pilot (PMID 39720104) with higher response rate in early-stage Long COVID-ME11.2 Numata 2021 — Commentary: Minocycline as Microglial Modulator
Key Findings::
- Editorial affirming minocycline's mechanism (microglial suppression) as theoretically sound for ME/CFS neuroinflammation
- Argues against “magic bullet” framing: ME/CFS heterogeneity means no single agent will benefit all patients
- Advocates stratified patient classification by disease onset, duration, and confirmed pathology before targeting specific interventionsRelevance:: Useful for framing therapeutic caution in the text: minocycline targets one thread of ME/CFS pathobiology (neuroinflammation) and should be positioned accordingly. Supports the precision-medicine framing of Section 15.7 treatment discussion. Certainty Assessment::
- *Quality:* Expert opinion (editorial, Internal Medicine)
- *Study type:* Commentary — no empirical data
- *Limitation:* Analytical only; no new evidence